Companies, institutions and data are cited as public industry context. These references do not imply partnership, endorsement, certification or a commercial relationship with our company.
Published company information
Use the linked sources to review the activities, dates and relationships explicitly described by this company.
Independent reference
This entry provides industry context. Mentioning a company or displaying its identity does not imply endorsement, affiliation or a commercial relationship with BLOPEP.
Sources and verification scope
Eli Lilly and Company Form 10-K, fiscal year 2025 ↗
SEC · filing by Eli Lilly and Company
Source details (original language)
- Scope
- Lilly reports reliance on China-based suppliers for portions of its supply chain
- Document section
- Manufacturing and supply, p. 21; third-party supply chain risk factors
- Limitations
- Does not identify Bolang, peptide purchases from Bolang, partnership, endorsement or certification.
- Claim verification date
- 2026-09-09
Related reading
Eli Lilly: supply-chain disclosure
The linked 2025 disclosure discusses China-based suppliers for parts of the supply chain, including chemical synthesis inputs.
Read details →